Elevate Your Enterprise Cutting-Edge Solutions from Xentria Inc

Sponsor: Xentria, Inc. Overall Status: Active - Recruiting. Phase. 1/2. Condition. Sarcoidosis. Lung Disease. Treatment. XTMAB-16 or Placebo ... Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, today announced a $25 million growth equity funding ... Xentria Investigative Site. Bloemfontein, South Africa, 9301. Central trial contact. Xentria Inc. Xentria Inc. Contact trial. Similar trials. A ... Xentria, Inc. 0 followers. ‌. Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic ... Tom Shea Summary. Tom Shea, based in Chicago, IL, US, is currently a Chief Executive Officer at Xentria, Inc.. Tom Shea brings experience from previous roles at ... Xentria is a biotech company focused on developing novel therapeutics to address unmet clinical needs. Xentria ... Focused on becoming a critical leader in the biopharma industry through a strong portfolio of products having purpose for patients. Driven to treat ... CHICAGO, IL June 27, 2023: Xentria Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, ... Xentria, Inc. Jessica Reeves' profile picture. logo. Jessica Reeves. Leukaemia Foundation. Company. AboutSupportTrust. Resources. IterateCompanies. Platform. Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million.